Literature DB >> 15062147

Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy.

David J Schwartz1, Brian J Davis, Richard J Vetter, Thomas M Pisansky, Michael G Herman, Torrence M Wilson, Wayne N LaJoie, Ann L Oberg.   

Abstract

PURPOSE: To identify factors associated with radiation exposure (RE) to operating room personnel during transperineal interstitial permanent prostate brachytherapy (TIPPB). METHODS AND MATERIALS: Between May 1998 and December 2000, 155 patients underwent TIPPB with fluoroscopic and ultrasound guidance. Data for each case included: operating room time (OT), anesthesia time (AT), fluoroscopy time (FT), number and type of seed implanted, total seed activity, and resident participation.
RESULTS: Personnel RE per case, FT, OT, and AT decreased as case number increased. Whole body badge dose per case decreased from a mean of 0.15+/-0.01 mSv (15+/-1 mrem) in 1998 to 0.074+/-0.011 mSv (7+/-1 mrem) in 2000. Average FT per case decreased from a mean of 17:27 min (range, 10:40-28:23) in 1998 to 12:08 min (range, 6:40-31:00) in 2000. Resident participation was associated with increased FT. Mean whole body and ring badge doses for the treating radiation oncologist were 0.0076 mSv/min (0.76 mrem/min) and 0.05 mSv/min (5.26 mrem/min) of FT, respectively.
CONCLUSIONS: FT was the predominant factor that related to RE during TIPPB. Treating radiation oncologists were exposed to less than 20 mSv per 100 cases, significantly less than other fluoroscopically guided procedures. Nonetheless, appropriate radiation exposure precautions during TIPPB should continue.

Entities:  

Mesh:

Year:  2003        PMID: 15062147     DOI: 10.1016/S1538-4721(03)00097-7

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  3 in total

1.  Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters.

Authors:  Hans Schiefer; Friedrich von Toggenburg; Wolf Seelentag; Ludwig Plasswilm; Gerhard Ries; Cornelius Lenggenhager; Hans-Peter Schmid; Thomas Leippold; Ladislav Prikler; Bernd Krusche; Jakob Roth; Daniel Engeler
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

Review 2.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

Review 3.  Low dose rate prostate brachytherapy.

Authors:  Bradley J Stish; Brian J Davis; Lance A Mynderse; Robert H McLaren; Christopher L Deufel; Richard Choo
Journal:  Transl Androl Urol       Date:  2018-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.